Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013
Sign Up to like & getrecommendations! Published in 2017 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2016.1263612
Abstract: Abstract Background: The objective of this study was to assess the timely disclosure of results of company-sponsored clinical trials related to all new medicines approved by the European Medicines Agency (EMA) during 2013. This is… read more here.
Keywords: new medicines; study; disclosure; company sponsored ... See more keywords
Abstract IA03: Targeting the DNA damage response to generate new medicines for cancer treatment
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.dnarepair16-ia03
Abstract: Cancers are characterized by high levels of genomic instability and endogenous DNA damage. Traditional cancer therapies include radiotherapy and DNA-damaging chemotherapy, but these treatments are associated with significant damage to normal tissue. These unwanted side… read more here.
Keywords: dna damage; new medicines; damage response; damage ... See more keywords
Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2019.01519
Abstract: Background Registration authorities evaluate effects of new medicines for chronic obstructive pulmonary disease (COPD) on airway obstruction, dyspnea, health status and exacerbations. To establish clinical relevance, minimal clinically important differences (MCIDs) are used. The aim… read more here.
Keywords: new medicines; efficacy endpoints; registration authorities; healthcare professionals ... See more keywords